Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Electrospun Carbothane-Based Drug-Enriched Scaffolds for Cardiovascular Devices : Drug Release, Hemocompatibility, Endothelialization, and Immunological Characterization. / Nazarkina, Zhanna K.; Chelobanov, Boris P.; Stepanova, Alena O. и др.
в: International Journal of Molecular Sciences, Том 27, № 11, 5081, 07.06.2026.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - Electrospun Carbothane-Based Drug-Enriched Scaffolds for Cardiovascular Devices
T2 - Drug Release, Hemocompatibility, Endothelialization, and Immunological Characterization
AU - Nazarkina, Zhanna K.
AU - Chelobanov, Boris P.
AU - Stepanova, Alena O.
AU - Imenov, Aznaur
AU - Laktionov, Pavel P.
N1 - Nazarkina, Z.K.; Chelobanov, B.P.; Stepanova, A.O.; Imenov, A.; Laktionov, P.P. Electrospun Carbothane-Based Drug-Enriched Scaffolds for Cardiovascular Devices: Drug Release, Hemocompatibility, Endothelialization, and Immunological Characterization. Int. J. Mol. Sci. 2026, 27, 5081. https://doi.org/10.3390/ijms27115081 This study was funded by the Russian Science Foundation grant number 25-25-00617
PY - 2026/6/7
Y1 - 2026/6/7
N2 - Polyurethane (PU) is widely used in medical products due to its biocompatibility and mechanical properties. Electrospinning (ES) was employed to produce PU-based scaffolds intended for cardiovascular devices (CVD) from blends of Carbothane (Carb) with human serum albumin (HSA), dimethylacetamide (DMA), and drugs. Sirolimus (SRL)—an immunosuppressive/anti-proliferative drug—and diclofenac (DF)—a nonsteroidal anti-inflammatory drug—were introduced into ES blends to produce drug-enriched scaffolds that prevent inflammation and cell overgrowth. The biocompatibility, stability, and mechanical properties of the scaffolds and SRL release were studied. The scaffolds possessed good mechanical properties and were stable in PBS and blood plasma (BP) for 120 days. The minimal SRL release rate was observed for the scaffold 3%Carb/10%HSA/DMA/SRL. A study of scaffold interaction with blood demonstrated good hemocompatibility of most scaffolds. A study of human gingival fibroblasts, endothelial cells (HUVEC and EA.hy926), and vascular smooth muscle cell interaction with scaffolds in vitro demonstrated variability in cell viability and pro-inflammatory interleukin IL-6 secretion, depending on both the scaffold composition and the cell type. The incorporation of DF into scaffolds decreased the concentration of IL-6 in the culture medium. The scaffold 3%Carb/10%HSA/DMA/SRL is the best choice for CVD in terms of hemocompatibility, endothelialization, and the induction of minimal inflammation.
AB - Polyurethane (PU) is widely used in medical products due to its biocompatibility and mechanical properties. Electrospinning (ES) was employed to produce PU-based scaffolds intended for cardiovascular devices (CVD) from blends of Carbothane (Carb) with human serum albumin (HSA), dimethylacetamide (DMA), and drugs. Sirolimus (SRL)—an immunosuppressive/anti-proliferative drug—and diclofenac (DF)—a nonsteroidal anti-inflammatory drug—were introduced into ES blends to produce drug-enriched scaffolds that prevent inflammation and cell overgrowth. The biocompatibility, stability, and mechanical properties of the scaffolds and SRL release were studied. The scaffolds possessed good mechanical properties and were stable in PBS and blood plasma (BP) for 120 days. The minimal SRL release rate was observed for the scaffold 3%Carb/10%HSA/DMA/SRL. A study of scaffold interaction with blood demonstrated good hemocompatibility of most scaffolds. A study of human gingival fibroblasts, endothelial cells (HUVEC and EA.hy926), and vascular smooth muscle cell interaction with scaffolds in vitro demonstrated variability in cell viability and pro-inflammatory interleukin IL-6 secretion, depending on both the scaffold composition and the cell type. The incorporation of DF into scaffolds decreased the concentration of IL-6 in the culture medium. The scaffold 3%Carb/10%HSA/DMA/SRL is the best choice for CVD in terms of hemocompatibility, endothelialization, and the induction of minimal inflammation.
KW - Carbothane
KW - biocompatibility
KW - drug release
KW - drug-eluting stents
KW - electrospinning
KW - endothelialization
KW - hemocompatibility
KW - polyurethane
KW - sirolimus
KW - vascular graft
KW - сиролимус
KW - электроформование
KW - высвобождение лекарственного препарата
KW - сосудистый протез
KW - стенты с лекарственным покрытием
KW - полиуретан
KW - Carbothane
KW - эндотелиализация
KW - биосовместимость
KW - гемосовместимость
UR - https://www.mendeley.com/catalogue/d9ac793b-f500-39ca-97bb-6e0856085bac/
UR - https://www.scopus.com/pages/publications/105041558240
U2 - 10.3390/ijms27115081
DO - 10.3390/ijms27115081
M3 - Article
C2 - 42278604
VL - 27
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
SN - 1661-6596
IS - 11
M1 - 5081
ER -
ID: 85413005